RU2641198C3 - Композиции glp-1 пептидов и их получение - Google Patents

Композиции glp-1 пептидов и их получение

Info

Publication number
RU2641198C3
RU2641198C3 RU2014141700A RU2014141700A RU2641198C3 RU 2641198 C3 RU2641198 C3 RU 2641198C3 RU 2014141700 A RU2014141700 A RU 2014141700A RU 2014141700 A RU2014141700 A RU 2014141700A RU 2641198 C3 RU2641198 C3 RU 2641198C3
Authority
RU
Russia
Prior art keywords
type
pharmaceutical composition
composition according
glp
granules
Prior art date
Application number
RU2014141700A
Other languages
English (en)
Other versions
RU2014141700A (ru
RU2641198C2 (ru
Original Assignee
Ново Нордиск А/С
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49221868&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RU2641198(C3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ново Нордиск А/С filed Critical Ново Нордиск А/С
Publication of RU2014141700A publication Critical patent/RU2014141700A/ru
Publication of RU2641198C2 publication Critical patent/RU2641198C2/ru
Application granted granted Critical
Publication of RU2641198C3 publication Critical patent/RU2641198C3/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Claims (9)

1. Фармацевтическая композиция для лечения диабета 2 типа, содержащая первый тип гранул и второй тип гранул, где указанный первый тип гранул содержит соль N-(8-(2-гидроксибензоил)амино)каприловой кислоты и не содержит пептид GLP-1, и где указанный второй тип гранул содержит пептид GLP-1 и не содержит соль N-(8-(2-гидроксибензоил)амино)каприловой кислоты, где указанная соль N-(8-(2-гидроксибензоил)амино)каприловой кислоты представляет собой SNAC, и указанный пептид GLP-1 представляет собой N-эпсилон26-[2-(2-{2-[2-(2-{2-[(S)-4-карбокси-4-(17-карбоксигептадеканоиламино)бутириламино]этокси}этокси)ацетиламино]этокси}этокси)ацетил][Аib8,Аrg34]GLР-1(7-37).
2. Фармацевтическая композициия по п. 1, где указанная композиция, кроме того, содержит более чем один фармацевтически приемлемый эксципиент.
3. Фармацевтическая композиция по п. 1, где указанный первый тип гранул, кроме того, содержит смазку, которая представляет собой стеарат магния.
4. Фармацевтическая композиция по п. 1, в которой указанный первый тип гранул, кроме того, содержит наполнитель, который представляет собой микрокристаллическую целлюлозу.
5. Фармацевтическая композиция по п. 1, в которой указанный второй тип гранул, кроме того, содержит наполнитель, который представляет собой микрокристаллическую целлюлозу.
6. Фармацевтическая композиция по п. 1, в которой указанный второй тип гранул, кроме того, содержит связующее вещество, которое представляет собой повидон.
7. Композиция по п. 1 в виде таблетки, где масса указанной таблетки составляет 400,7, 404,7 или 411,7 мг.
8. Фармацевтическая композиция по любому из пп. 1-7 для применения в медицине, где указанная композиция вводится перорально.
9. Фармацевтическая композиция по любому из пп. 1-7 для применения в лечении диабета 2 типа, где указанная композиция вводится перорально.
RU2014141700A 2012-03-22 2013-03-15 Композиции glp-1 пептидов и их получение RU2641198C3 (ru)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
EP12160743.6 2012-03-22
EP12160743 2012-03-22
US201361748840P 2013-01-04 2013-01-04
US61/748,840 2013-01-04
EP13153459.6 2013-01-31
EP13153459 2013-01-31
PCT/EP2013/055362 WO2013139694A1 (en) 2012-03-22 2013-03-15 Compositions of glp-1 peptides and preparation thereof

Publications (3)

Publication Number Publication Date
RU2014141700A RU2014141700A (ru) 2016-05-20
RU2641198C2 RU2641198C2 (ru) 2018-01-16
RU2641198C3 true RU2641198C3 (ru) 2021-12-10

Family

ID=49221868

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2014141700A RU2641198C3 (ru) 2012-03-22 2013-03-15 Композиции glp-1 пептидов и их получение

Country Status (21)

Country Link
US (5) US10933120B2 (ru)
EP (3) EP2827885B1 (ru)
JP (1) JP6001158B2 (ru)
KR (1) KR102072202B1 (ru)
CN (2) CN104203266B (ru)
AU (2) AU2013234496B2 (ru)
BR (1) BR112014023374B1 (ru)
CA (1) CA2868188A1 (ru)
DK (1) DK2827885T3 (ru)
ES (2) ES2690553T3 (ru)
HR (2) HRP20231060T1 (ru)
HU (2) HUE062740T2 (ru)
LT (1) LT2827885T (ru)
MX (1) MX353067B (ru)
MY (1) MY171146A (ru)
PL (2) PL3488857T3 (ru)
RS (2) RS57727B1 (ru)
RU (1) RU2641198C3 (ru)
SI (1) SI2827885T1 (ru)
WO (1) WO2013139694A1 (ru)
ZA (1) ZA201406250B (ru)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3326620T3 (da) 2010-12-16 2020-05-25 Novo Nordisk As Faste sammensætninger omfattende en glp-1-agonist og et salt af n-(8-(2- hydroxybenzoyl)amino)caprylsyre
KR101972836B1 (ko) 2011-04-12 2019-04-29 노보 노르디스크 에이/에스 이중 아실화된 ｇｌｐ-1 유도체
PT2827885T (pt) * 2012-03-22 2018-11-05 Novo Nordisk As Composições de péptidos glp-1 e sua preparação
US10335369B2 (en) 2012-03-22 2019-07-02 Novo Nordisk A/S Compositions comprising a delivery agent and preparation thereof
DK2827845T3 (en) * 2012-03-22 2019-04-01 Novo Nordisk As COMPOSITIONS INCLUDING A PROCEDURE AND PREPARING THEREOF
HUE062740T2 (hu) 2012-03-22 2023-12-28 Novo Nordisk As GLP-1 peptidek készítményei és elõállításuk
ES2871328T3 (es) 2012-06-20 2021-10-28 Novo Nordisk As Formulación de comprimido que comprende un péptido y un agente de suministro
EP2991671B1 (en) * 2013-05-02 2018-08-15 Novo Nordisk A/S Oral dosing of glp-1 compounds
DK3006045T3 (en) 2014-10-07 2017-07-17 Cyprumed Gmbh Pharmaceutical formulations for oral administration of peptide or protein drugs
WO2017060500A1 (en) 2015-10-07 2017-04-13 Cyprumed Gmbh Pharmaceutical formulations for the oral delivery of peptide drugs
US10946074B2 (en) 2016-03-03 2021-03-16 Novo Nordisk A/S GLP-1 derivatives and uses thereof
CN108606957A (zh) * 2016-12-13 2018-10-02 南京星银药业集团有限公司 一种含索马鲁肽的口服缓释制剂及其制备方法
AR112015A1 (es) 2017-06-09 2019-09-11 Novo Nordisk As Composiciones sólidas para administración oral
CN111683676B (zh) 2018-02-02 2024-06-18 诺和诺德股份有限公司 包含glp-1激动剂、n-(8-(2-羟基苯甲酰基)氨基)辛酸的盐和润滑剂的固体组合物
WO2019173571A1 (en) * 2018-03-09 2019-09-12 Northwestern University Insulin-loaded metal-organic frameworks
EP3773475A1 (en) 2018-04-06 2021-02-17 Cyprumed GmbH Pharmaceutical compositions for the transmucosal delivery of therapeutic peptides and proteins
TWI829687B (zh) * 2018-05-07 2024-01-21 丹麥商諾佛 儂迪克股份有限公司 包含glp-1促效劑與n-(8-(2-羥基苯甲醯基)胺基)辛酸之鹽的固體組成物
JP7422754B2 (ja) 2018-10-26 2024-01-26 ノヴォ ノルディスク アー／エス 安定性セマグルチド組成物およびその使用
CN111265654B (zh) * 2018-12-05 2023-05-16 江苏恒瑞医药股份有限公司 Glp-1类似物的药物组合物及其制备方法
US11617965B2 (en) 2018-12-21 2023-04-04 Novo Nordisk A/S Process of spray drying of GLP-1 peptide
EP3914383A1 (en) 2019-01-24 2021-12-01 Novo Nordisk A/S Roller compactor and method of dry granulation using a roller compactor
EP3938094A1 (en) * 2019-03-15 2022-01-19 Novo Nordisk A/S Process for spray drying a glp-1 peptide
MX2022000889A (es) 2019-08-07 2022-02-14 Novo Nordisk As Composiciones solidas que comprenden un derivado de egf(a) y una sal de acido n-(8-(2-hidroxibenzoil)amino)caprilico.
ES2969534T3 (es) * 2019-08-07 2024-05-21 Novo Nordisk As Composición sólida que comprende un compuesto del PYY y una sal de ácido N-(8-(2-hidroxibenzoil)amino)caprílico
JP2023502004A (ja) 2019-11-07 2023-01-20 ノヴォ ノルディスク アー／エス Ｇｌｐ－１作動薬、ｓｇｌｔ２阻害剤、およびｎ－（８－（２－ヒドロキシベンゾイル）アミノ）カプリル酸の塩を含む固形組成物
MX2022004718A (es) 2019-11-07 2022-06-08 Novo Nordisk As Omposiciones sólidas que comprenden un inhibidor de proproteína convertasa subtilisina/kexina tipo 9 (pcsk9) y una sal de ácido n-(8-(2-hidroxibenzoil)amino)caprílico.
WO2021219710A1 (en) * 2020-04-29 2021-11-04 Novo Nordisk A/S Solid compositions comprising a glp-1 agonist and histidine
TW202227474A (zh) 2020-12-18 2022-07-16 丹麥商諾佛 儂迪克股份有限公司 Ｇｌｐ－１及澱粉素受體之共促效劑
WO2022235991A1 (en) * 2021-05-07 2022-11-10 Eli Lilly And Company Erodible tablet
US20230000764A1 (en) * 2021-06-11 2023-01-05 Boa Nutrition, Inc. Pressurized nutritional supplement delivery
EP4360645A1 (en) 2021-06-25 2024-05-01 Gan & Lee Pharmaceuticals Co., Ltd. Pharmaceutical composition containing glp-1 compound
KR20240036563A (ko) 2021-07-15 2024-03-20 노보 노르디스크 에이/에스 N-(8-(2-하이드록시벤조일)아미노)카프릴산의 염을 포함하는 정제
WO2023012263A1 (en) 2021-08-04 2023-02-09 Novo Nordisk A/S Solid oral peptide formulations
WO2023065231A1 (en) * 2021-10-21 2023-04-27 Guangzhou Dazhou Biomedicine Ltd. Oral delivery of therapeutic agents
WO2023098777A1 (zh) * 2021-12-01 2023-06-08 江苏恒瑞医药股份有限公司 Glp-1和gip受体双重激动剂的药物组合物及其用途
WO2023174433A1 (en) * 2022-03-18 2023-09-21 Smart Pharmaceutical (Suzhou) Co., Ltd. Solid, semisolid, or liquid compositions for augmenting the stability, permeability and bioavailability of active pharmaceutical substances
CN114984191B (zh) * 2022-07-04 2022-10-25 北京惠之衡生物科技有限公司 一种多肽类药物口服递送组合物
WO2024110614A1 (en) 2022-11-25 2024-05-30 Novo Nordisk A/S Oral administration of peptide therapeutics, such as glp-1

Family Cites Families (192)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0238259B1 (en) 1986-03-12 1993-09-29 American Cyanamid Company Macrolide compounds
EP0512042B1 (en) 1990-01-24 1998-04-08 BUCKLEY, Douglas I. Glp-1 analogs useful for diabetes treatment
US5545618A (en) 1990-01-24 1996-08-13 Buckley; Douglas I. GLP-1 analogs useful for diabetes treatment
DK39892D0 (da) 1992-03-25 1992-03-25 Bernard Thorens Peptid
AU685803B2 (en) 1993-03-29 1998-01-29 University Of Cincinnati, The Analogs of peptide YY and uses thereof
US5705483A (en) 1993-12-09 1998-01-06 Eli Lilly And Company Glucagon-like insulinotropic peptides, compositions and methods
EP0803255A4 (en) 1994-06-03 1999-06-30 Tsumura & Co DRUG
US5512549A (en) 1994-10-18 1996-04-30 Eli Lilly And Company Glucagon-like insulinotropic peptide analogs, compositions, and methods of use
US5574010A (en) 1994-11-14 1996-11-12 The Regents Of The University Of California Treatment of pancreatic tumors with peptide YY and analogs thereof
US5869602A (en) 1995-03-17 1999-02-09 Novo Nordisk A/S Peptide derivatives
US5650386A (en) 1995-03-31 1997-07-22 Emisphere Technologies, Inc. Compositions for oral delivery of active agents
US5866536A (en) 1995-03-31 1999-02-02 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
CN1151836C (zh) 1995-03-31 2004-06-02 艾米斯菲尔技术有限公司 用作传送活性剂的化合物和组合物
SE9600070D0 (sv) 1996-01-08 1996-01-08 Astra Ab New oral pharmaceutical dosage forms
US6458924B2 (en) 1996-08-30 2002-10-01 Novo Nordisk A/S Derivatives of GLP-1 analogs
US7235627B2 (en) 1996-08-30 2007-06-26 Novo Nordisk A/S Derivatives of GLP-1 analogs
BRPI9711437B8 (pt) 1996-08-30 2021-05-25 Novo Nordisk As derivados de glp-1
US6268343B1 (en) 1996-08-30 2001-07-31 Novo Nordisk A/S Derivatives of GLP-1 analogs
ATE366584T1 (de) 1996-11-12 2007-08-15 Novo Nordisk As Verwendung von glp-1 peptiden
WO1998020885A1 (en) 1996-11-13 1998-05-22 University Of Cincinnati Analogs of peptide yy and uses thereof
US5773647A (en) 1997-02-07 1998-06-30 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
EP0908515A3 (en) 1997-09-16 2000-04-26 Smithkline Beecham Plc Pancreatic polypeptide
WO1999043705A1 (en) 1998-02-27 1999-09-02 Novo Nordisk A/S N-terminally truncated glp-1 derivatives
JP2002512175A (ja) 1998-02-27 2002-04-23 ノボ ノルディスク アクティーゼルスカブ Ｇｌｐ−１類似体の誘導体類
WO1999043708A1 (en) 1998-02-27 1999-09-02 Novo Nordisk A/S Glp-1 derivatives of glp-1 and exendin with protracted profile of action
AU2610899A (en) 1998-02-27 1999-09-15 Novo Nordisk A/S N-terminally modified glp-1 derivatives
AU2610799A (en) 1998-02-27 1999-09-15 Novo Nordisk A/S Glp-1 derivatives with helix-content exceeding 25 per cent, forming partially structured micellar-like aggregates
US6046167A (en) 1998-03-25 2000-04-04 University Of Cincinnati Peptide YY analogs
CA2334298C (en) 1998-06-08 2008-01-08 Schering Corporation Neuropeptide y5 receptor antagonists
SE9802080D0 (sv) * 1998-06-11 1998-06-11 Hellstroem Pharmaceutical composition for the treatment of functional dyspepsia and/or irritable bowel syndrome and new use of substances therein
DE69911975T2 (de) 1998-07-31 2004-09-09 Novo Nordisk A/S In-vitro stimulation von beta zellen vermehrung
MY155270A (en) 1998-09-24 2015-09-30 Lilly Co Eli Use of glp-1 or analogs in treatment of stroke
NZ527241A (en) 1998-12-07 2004-12-24 Sod Conseils Rech Applic Analogues of GLP-1
EP1149066B1 (en) 1999-02-05 2005-11-09 Emisphere Technologies, Inc. Method of preparing alkylated salicylamides
US7658938B2 (en) 1999-02-22 2010-02-09 Merrion Reasearch III Limited Solid oral dosage form containing an enhancer
JP2002537321A (ja) 1999-02-22 2002-11-05 エラン コーポレイション ピーエルスィー 促進剤を含む固体経口剤形
WO2000048589A1 (en) 1999-02-22 2000-08-24 Emisphere Holdings, Inc. Solid oral dosage form containing heparin or a heparinoid in combination with a carrier
EP1175443A1 (en) 1999-04-30 2002-01-30 Amylin Pharmaceuticals, Inc. Modified exendins and exendin agonists
US7601691B2 (en) 1999-05-17 2009-10-13 Conjuchem Biotechnologies Inc. Anti-obesity agents
ATE252601T1 (de) 1999-05-17 2003-11-15 Conjuchem Inc Lang wirkende insulinotrope peptide
EP1076066A1 (en) 1999-07-12 2001-02-14 Zealand Pharmaceuticals A/S Peptides for lowering blood glucose levels
GB9923436D0 (en) 1999-10-04 1999-12-08 American Home Prod Pharmaceutical compositions
US6793934B1 (en) 1999-12-08 2004-09-21 Shire Laboratories, Inc. Solid oral dosage form
US7262325B2 (en) 2000-06-02 2007-08-28 Emisphere Technologies, Inc. Method of preparing salicylamides
US7049283B2 (en) 2000-12-06 2006-05-23 Novartis Ag Pharmaceutical compositions for the oral delivery of pharmacologically active agents
PL393178A1 (pl) 2000-12-07 2011-02-14 Eli Lilly And Company Heterogenne białko fuzyjne, kompozycja farmaceutyczna do leczenia pacjentów z cukrzycą insulino-niezależną i kompozycja farmaceutyczna do leczenia pacjentów z otyłością
US7199217B2 (en) 2000-12-13 2007-04-03 Eli Lilly And Company Amidated glucagon-like peptide-1
MXPA03005388A (es) 2000-12-14 2003-09-25 Amylin Pharmaceuticals Inc Peptido yy y agonistas de peptido yy para el tratamiento de desordenes metabolicos.
GB0102075D0 (en) * 2001-01-26 2001-03-14 Astrazeneca Ab Process
US6589938B2 (en) 2001-06-29 2003-07-08 National University Of Singapore Use of angiotensin I derivatives as an agent for the treatment and prevention of infarction-related cardiac injuries and disorders
US20030068356A1 (en) 2001-07-10 2003-04-10 Pather S. Indiran Sequential drug delivery systems
DE60228972D1 (de) 2001-07-31 2008-10-30 Us Gov Health & Human Serv Glp 1 exendin 4 peptidanaloga und deren verwendungen
US7459432B2 (en) 2001-09-24 2008-12-02 Imperial College Innovations Ltd. Modification of feeding behavior
EP1461031B1 (en) 2001-11-29 2016-06-29 Emisphere Technologies, Inc. Formulations for oral administration of cromolyn sodium
US8058233B2 (en) 2002-01-10 2011-11-15 Oregon Health And Science University Modification of feeding behavior using PYY and GLP-1
MXPA04007427A (es) 2002-02-01 2004-10-11 Pfizer Prod Inc Formulaciones de azitromicina granuladas por via seca.
EP1478233B1 (en) 2002-02-20 2016-11-09 Emisphere Technologies, Inc. Method for administering glp-1 molecules
DK1525219T3 (da) 2002-07-04 2009-09-07 Zealand Pharma As GLP-1 og fremgangsm der til behandling af diabetes
JP2004131398A (ja) 2002-10-08 2004-04-30 Taihei Chemical Industrial Co Ltd 錠剤用滑沢剤
US7811989B2 (en) 2003-01-17 2010-10-12 Ipsen Pharma S.A.S. Peptide YY analogs
US20050059605A1 (en) 2003-01-31 2005-03-17 Krishna Peri Chemically modified metabolites of regulatory peptides and methods of producing and using same
CN1832959A (zh) 2003-03-19 2006-09-13 伊莱利利公司 聚乙二醇连接的glp－1化合物
NZ543274A (en) 2003-05-14 2007-12-21 Emisphere Tech Inc Compositions for delivering peptide YY and PYY agonists
US7572581B2 (en) 2003-06-30 2009-08-11 Roche Molecular Systems, Inc. 2′-terminator nucleotide-related methods and systems
BRPI0412458A (pt) 2003-07-11 2006-10-17 Novartis Ag composições farmacêuticas oralmente dosadas compreendendo um agente de liberação na forma micronizada
WO2005014049A2 (en) 2003-08-08 2005-02-17 Novo Nordisk A/S Synthesis and application of new structural well defined branched polymers as conjugating agents for peptides
CN101380476A (zh) 2003-09-19 2009-03-11 诺沃挪第克公司 治疗肽的清蛋白结合型衍生物
CA2539253A1 (en) 2003-09-19 2005-03-31 Novo Nordisk A/S Albumin-binding derivatives of therapeutic peptides
WO2005028516A2 (en) 2003-09-19 2005-03-31 Novo Nordisk A/S Albumin-binding derivatives of therapeutic peptides
KR101243648B1 (ko) 2003-11-20 2013-03-14 노보 노르디스크 에이/에스 제조 및 주사 장치용에 최적인 프로필렌 글리콜 함유펩티드 제제
BRPI0417717A (pt) 2003-12-18 2007-04-03 Novo Nordisk As composto, composição farmacêutica, e, uso de um composto
EP1696962A2 (en) 2003-12-18 2006-09-06 Novo Nordisk A/S Novel glp-1 analogues linked to albumin-like agents
US20060286129A1 (en) 2003-12-19 2006-12-21 Emisphere Technologies, Inc. Oral GLP-1 formulations
EP2335715A3 (en) 2004-02-11 2013-12-18 Amylin Pharmaceuticals, LLC Pancreatic polypeptide family motifs and polypeptides comprising the same
WO2005077072A2 (en) 2004-02-11 2005-08-25 Amylin Pharmaceuticals, Inc. Hybrid polypeptides with selectable properties
JP2007529463A (ja) 2004-03-17 2007-10-25 ７ティーエム ファーマ エイ／エス 治療的介入のためのｙ４選択性レセプターアゴニスト
WO2005089790A2 (en) 2004-03-17 2005-09-29 7Tm Pharma A/S Y2/y4 selective receptor agonists for therapeutic interventions
US20090186811A1 (en) 2004-03-17 2009-07-23 Thue Schwartz Y2 Selective Receptor Agonists for Therapeutic Interventions
AU2005224026A1 (en) 2004-03-17 2005-09-29 7Tm Pharma A/S Y2 selective receptor agonists for therapeutic interventions
WO2005099672A1 (en) 2004-04-13 2005-10-27 Ranbaxy Laboratories Limited A modified release pharmaceutical formulation comprising amoxicillin and clavulanate
NZ550894A (en) 2004-05-06 2011-02-25 Emisphere Tech Inc Solid dosage form of wetted heparin
CA2897225C (en) 2004-05-06 2017-12-05 Emisphere Technologies, Inc. Crystalline polymorphic forms of monosodium n-[8-(2-hydroxybenzoyl)amino]caprylate
WO2005112633A2 (en) * 2004-05-14 2005-12-01 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
GB0412181D0 (en) 2004-06-01 2004-06-30 Celltech R&D Ltd Biological products
WO2005121090A1 (en) 2004-06-02 2005-12-22 Abbott Laboratories Substituted piperidines that have antiangiogenic activity
CN101010339B (zh) * 2004-07-02 2011-11-09 布里斯托尔-迈尔斯斯奎布公司 人类胰高血糖素样肽-1调节剂及它们在治疗糖尿病及相关病况中的用途
TW200611704A (en) 2004-07-02 2006-04-16 Bristol Myers Squibb Co Human glucagon-like-peptide-1 modulators and their use in the treatment of diabetes and related conditions
JP2008507477A (ja) 2004-07-08 2008-03-13 ノボ　ノルディスク　アクティーゼルスカブ ポリペプチド延長タグ
CA2573512C (en) 2004-07-12 2014-09-23 Emisphere Technologies, Inc. Compositions for delivering peptide yy and pyy agonists
US7994119B2 (en) 2004-07-19 2011-08-09 University Of Cincinnati Compounds for control of appetite
US20060078622A1 (en) 2004-08-13 2006-04-13 Emisphere Technologies, Inc. Pharmaceutical formulations containing microparticles or nanoparticles of a delivery agent
WO2006049681A2 (en) 2004-08-30 2006-05-11 Bayer Pharmaceuticals Corporation Selective neuropeptide y2 receptor agonists
JP2008515856A (ja) 2004-10-07 2008-05-15 ノボ ノルディスク アクティーゼルスカブ 遅延性ｇｌｐ−１化合物
JP5107713B2 (ja) 2004-10-07 2012-12-26 ノヴォ ノルディスク アー／エス 遅延性のエキセンディン−４化合物
US7410949B2 (en) 2005-01-18 2008-08-12 Hoffmann-La Roche Inc. Neuropeptide-2 receptor (Y-2R) agonists and uses thereof
ES2540929T3 (es) 2005-02-01 2015-07-14 Emisphere Technologies, Inc. Sistema de administración de retención gástrica y liberación controlada
ES2438145T3 (es) 2005-02-02 2014-01-16 Novo Nordisk A/S Nuevos derivados de insulina
WO2006096515A2 (en) 2005-03-04 2006-09-14 Biorexis Pharmaceutical Corporation Modified transferrin fusion proteins
GB0504857D0 (en) 2005-03-09 2005-04-13 Imp College Innovations Ltd Novel compounds and their effects on feeding behaviour
TWI362392B (en) 2005-03-18 2012-04-21 Novo Nordisk As Acylated glp-1 compounds
JP2008533104A (ja) 2005-03-18 2008-08-21 ノボ ノルディスク アクティーゼルスカブ Ｇｌｐ−１受容体の二量体ペプチドアゴニスト
WO2006097535A2 (en) 2005-03-18 2006-09-21 Novo Nordisk A/S Peptide agonists of the glucagon family with secretin like activity
ES2484796T3 (es) 2005-03-18 2014-08-12 Novo Nordisk A/S Compuestos de GLP-1 extendidos
EP1863449A2 (en) 2005-03-28 2007-12-12 Dexcel Pharma Technologies Ltd. Controlled absorption of statins in the intestine
PE20061448A1 (es) 2005-05-26 2006-12-17 Bristol Myers Squibb Co Compuestos polipeptidos como moduladores del peptido 1 similar al glucagon humano
WO2007008778A2 (en) 2005-07-11 2007-01-18 Nastech Pharmaceutical Company Inc. Formulations for enhanced mucosal delivery of pyy
US8975227B2 (en) 2005-07-15 2015-03-10 Emisphere Technologies, Inc. Intraoral dosage forms of glucagon
US20090203581A1 (en) 2005-07-18 2009-08-13 Novo Nordisk A/S Novel Peptides for Use in the Treatment of Obesity
JP5693817B2 (ja) 2005-08-19 2015-04-01 アミリン・ファーマシューティカルズ, リミテッド・ライアビリティ・カンパニーAmylin Pharmaceuticals, Llc 糖尿病の治療法および体重の減少法
US20070049557A1 (en) 2005-08-24 2007-03-01 Hashim Ahmed Solid pharmaceutical dosage forms comprising bisphosphonates and modified amino acid carriers
US8022035B2 (en) 2005-09-21 2011-09-20 7Tm Pharma A/S Y4 selective receptor agonists for therapeutic interventions
EA200800875A1 (ru) 2005-09-21 2008-08-29 7ТиЭм ФАРМА А/С Рецепторные агонисты, селективные к y2 рецептору, для терапевтического воздействия
WO2007061434A2 (en) 2005-11-10 2007-05-31 Nastech Pharmaceutical Company Inc. A pharmaceutical formulation of glp-1 and its use for treating a metabolic syndrome
CN101309674A (zh) 2005-11-17 2008-11-19 诺瓦提斯公司 药物组合物
KR101059602B1 (ko) 2005-12-07 2011-08-25 에프. 호프만-라 로슈 아게 신경펩타이드 2 수용체 작용물질
BRPI0620571A2 (pt) 2005-12-08 2011-11-22 Nastech Pharm Co formulação farmacêutica aquosa, forma de dosagem de exendina, solução aquosa, uso de uma formulação farmacêutica, e uso de uma formulação farmacêutica aquosa
EP1963343A1 (en) 2005-12-14 2008-09-03 Novo Nordisk A/S Polypeptide protracting tags
US20070197445A1 (en) 2006-01-18 2007-08-23 University Of Cincinnati Compounds for control of appetite
JP5412273B2 (ja) 2006-03-21 2014-02-12 アミリン・ファーマシューティカルズ，リミテッド・ライアビリティ・カンパニー ペプチド−ぺプチダーゼ阻害剤及びその使用
BRPI0710503A2 (pt) 2006-04-07 2011-08-16 Merrion Res Iii Ltd uso de uma composição farmacêutica, composição farmacêutica, e, forma de dosagem oral
US8927015B2 (en) 2006-04-12 2015-01-06 Emisphere Technologies, Inc. Formulations for delivering insulin
MX2008014061A (es) 2006-05-09 2008-11-14 Novo Nordisk As Derivado de insulina.
US20070292512A1 (en) 2006-06-09 2007-12-20 Merrion Research Ii Limited Solid Oral Dosage Form Containing an Enhancer
JP5475443B2 (ja) 2006-06-28 2014-04-16 エミスフェアー・テクノロジーズ・インク 硝酸ガリウム製剤
GB0613196D0 (en) 2006-07-03 2006-08-09 Imp Innovations Ltd Novel compounds and their effects on feeding behaviour
ES2296529B1 (es) 2006-08-07 2009-04-01 Laboratorios Farmaceuticos Rovi, S.A. Composicion farmaceutica con promotores de absorcion.
US20090318353A1 (en) 2006-08-25 2009-12-24 Novo Nordisk A/S Acylated Exendin-4 Compounds
CN101506147B (zh) 2006-09-07 2012-03-21 霍夫曼-拉罗奇有限公司 用于制备snac（n-（8-[2-羟基苯甲酰基]-氨基）辛酸钠）的方法
TWI430806B (zh) 2006-09-13 2014-03-21 Smithkline Beecham Corp 用於投與長效降血糖藥劑之方法
PE20080845A1 (es) 2006-09-22 2008-08-13 Novartis Ag Metodo para fabricar tabletas que contienen agentes farmacologicamente activos
GB0621973D0 (en) 2006-11-03 2006-12-13 Philogen Spa Binding molecules and uses thereof
US20100069410A1 (en) 2006-12-01 2010-03-18 Emisphere Technologies Inc. acyclovir formulations
US20090099074A1 (en) 2007-01-10 2009-04-16 Conjuchem Biotechnologies Inc. Modulating food intake
JP2010516652A (ja) 2007-01-18 2010-05-20 ノボ・ノルデイスク・エー／エス 肥満の治療に使用される新規ペプチド
US20100022446A1 (en) 2007-01-18 2010-01-28 Novo Nordisk A/S Use of Peptides in Combination with Surgical Intervention for the Treatment of Obesity
CA2679782C (en) 2007-03-02 2015-02-17 Novartis Ag Oral administration of a calcitonin
GB0708226D0 (en) 2007-04-27 2007-06-06 7Tm Pharma As Y-receptor agonists
EP2171080A4 (en) 2007-06-12 2010-10-27 Glaxosmithkline Llc METHODS OF PROTEIN DETECTION IN PLASMA
US8093689B2 (en) * 2007-07-02 2012-01-10 Infineon Technologies Ag Attachment member for semiconductor sensor device
EP2167535A2 (en) 2007-07-09 2010-03-31 Imperial Innovations Limited Human pancreatic polypeptide (hpp) analogues and their effects on feeding behaviour
EP2182956A2 (en) 2007-08-29 2010-05-12 The Regents of the University of California Salicylanilide modified peptides for use as oral therapeutics
ES2550363T3 (es) 2007-09-05 2015-11-06 Novo Nordisk A/S Derivados truncados de GLP-1 y su uso terapéutico
ES2532116T3 (es) 2007-09-05 2015-03-24 Novo Nordisk A/S Péptidos derivados con A-B-C-D y sus usos terapéuticos
WO2009030738A1 (en) 2007-09-05 2009-03-12 Novo Nordisk A/S Glucagon-like peptide-1 derivatives and their pharmaceutical use
AU2008303922A1 (en) 2007-09-11 2009-04-02 Mondobiotech Laboratories Ag Use of the peptide His-Ser-Leu-Gly-Lys-Trp-Leu-Gly-His-Pro-Asp-Lys-Phe alone or in combination with the peptide Gly-Ard-Gly-Asp-Asn-Pro-OH as a therapeutic agent
WO2009042922A2 (en) 2007-09-27 2009-04-02 Amylin Pharmaceuticals, Inc. Peptide-peptidase inhibitor conjugates and methods of making and using same
JP5868594B2 (ja) 2007-10-16 2016-02-24 バイオコン・リミテッドＢｉｏｃｏｎ Ｌｉｍｉｔｅｄ 経口投与可能な固形医薬組成物及びそのプロセス
PL2215047T3 (pl) 2007-11-02 2014-05-30 Emisphere Tech Inc Sposób leczenia niedoborów witaminy b12
US20090124639A1 (en) * 2007-11-06 2009-05-14 Emisphere Technologies Inc. valacyclovir formulations
US20100317057A1 (en) 2007-12-28 2010-12-16 Novo Nordisk A/S Semi-recombinant preparation of glp-1 analogues
BRPI0912615A2 (pt) 2008-05-16 2016-01-26 Novo Nordisk As agonistas de receptor y2 e/ou y4 de longa ação
ES2823233T3 (es) 2008-08-18 2021-05-06 Entera Bio Ltd Métodos y composiciones para la administración oral de proteínas
EP2340049B1 (en) 2008-09-12 2015-11-11 Novo Nordisk A/S Method of acylating a peptide or protein
US8299023B2 (en) 2008-09-17 2012-10-30 Hoffmann-La Roche Inc. Neuropeptide-2 receptor (Y-2R) agonists
GB0817067D0 (en) 2008-09-18 2008-10-22 7Tm Pharma As Intestinal treatment
ES2445540T3 (es) 2008-10-15 2014-03-03 Bayer Cropscience Ag Uso de ditiina-tetracarboximidas para combatir hongos fitopatógenos
KR20110097807A (ko) 2008-11-05 2011-08-31 에프. 호프만-라 로슈 아게 뉴로펩티드-2-수용체(ｙ-2ｒ) 작용제 및 이의 용도
CN101463081B (zh) 2009-01-12 2012-07-04 华东师范大学 一种glp-1衍生物
JP2012517977A (ja) 2009-02-13 2012-08-09 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｄｐｐ−４阻害剤（リナグリプチン）を任意で他の抗糖尿病薬と組み合わせて含む抗糖尿病薬
JP5584236B2 (ja) 2009-02-20 2014-09-03 イプセン ファルマ ソシエテ パール アクシオン サンプリフィエ 神経ペプチドｙ受容体結合化合物を有する細胞毒性コンジュゲート
AR077956A1 (es) 2009-09-14 2011-10-05 Bayer Cropscience Ag Combinaciones de compuestos activos
JP2013505221A (ja) 2009-09-18 2013-02-14 ノヴォ ノルディスク アー／エス 長時間作用性ｙ２受容体アゴニスト
CA2776302A1 (en) 2009-10-13 2011-04-21 F. Hoffmann-La Roche Ag Neuropeptide-2 receptor (y-2r) agonists
JP2013510829A (ja) 2009-11-13 2013-03-28 ノヴォ ノルディスク アー／エス 長時間作用型ｙ２受容体アゴニスト
WO2011084618A2 (en) 2009-12-16 2011-07-14 Nod Pharmaceuticals, Inc. Compositions and methods for oral drug delivery
EP2513141B1 (en) 2009-12-16 2017-03-01 Novo Nordisk A/S Glp-1 analogues and derivatives
US20110182985A1 (en) 2010-01-28 2011-07-28 Coughlan David C Solid Pharmaceutical Composition with Enhancers and Methods of Preparing thereof
WO2011109787A1 (en) 2010-03-05 2011-09-09 Conjuchem, Llc Methods of administering insulinotropic peptides
WO2011116139A2 (en) 2010-03-16 2011-09-22 Chiasma Inc. Improved pharmaceutical compositions and methods of delivery
US9040660B2 (en) 2010-04-20 2015-05-26 Novo Nordisk A/S Long-acting gastrin derivatives
MX2012012383A (es) 2010-04-30 2012-11-30 Sanwa Kagaku Kenkyusho Co Peptido para mejorar la bioestabilidad de una sustancia bioactica y sustancia bioactiva que tiene bioestabilidad mejorada.
CN102946875A (zh) 2010-05-05 2013-02-27 贝林格尔.英格海姆国际有限公司 组合疗法
DE202010015867U1 (de) 2010-11-25 2011-05-05 Buchhalter, Thomas Elektromechanische Halterung zur Aufnahme von Navigations- und Kommunikationsgeräte im KFZ
DK3326620T3 (da) 2010-12-16 2020-05-25 Novo Nordisk As Faste sammensætninger omfattende en glp-1-agonist og et salt af n-(8-(2- hydroxybenzoyl)amino)caprylsyre
GB201101459D0 (en) 2011-01-27 2011-03-16 Imp Innovations Ltd Novel compounds and thier effects on fedding behaviour
KR101972836B1 (ko) 2011-04-12 2019-04-29 노보 노르디스크 에이/에스 이중 아실화된 ｇｌｐ-1 유도체
WO2013009545A1 (en) 2011-07-08 2013-01-17 Amylin Pharmaceuticals, Inc. Engineered polypeptides having enhanced duration of action with reduced immunogenicity
US10335369B2 (en) 2012-03-22 2019-07-02 Novo Nordisk A/S Compositions comprising a delivery agent and preparation thereof
HUE062740T2 (hu) 2012-03-22 2023-12-28 Novo Nordisk As GLP-1 peptidek készítményei és elõállításuk
DK2827845T3 (en) 2012-03-22 2019-04-01 Novo Nordisk As COMPOSITIONS INCLUDING A PROCEDURE AND PREPARING THEREOF
US20150141336A1 (en) 2012-05-29 2015-05-21 Novo Nordisk A/S Pancreatic Peptide Compounds and Use
ES2871328T3 (es) 2012-06-20 2021-10-28 Novo Nordisk As Formulación de comprimido que comprende un péptido y un agente de suministro
SI2866825T1 (sl) 2012-07-01 2020-07-31 Novo Nordisk A/S Uporaba dolgo delujočih peptidov GLP-1
CN105263957A (zh) 2013-05-02 2016-01-20 葛兰素史克知识产权开发有限公司 治疗肽
EP2991671B1 (en) 2013-05-02 2018-08-15 Novo Nordisk A/S Oral dosing of glp-1 compounds
JP6629198B2 (ja) 2013-11-15 2020-01-15 ノヴォ ノルディスク アー／エス ３５位にβ−ホモアルギニン置換を有するＨＰＹＹ（１−３６）
TWI661835B (zh) 2013-11-15 2019-06-11 丹麥商諾佛 儂迪克股份有限公司 選擇性ｐｙｙ化合物及其用途
US20180050096A1 (en) 2015-02-09 2018-02-22 Entera Bio Ltd. Treatment of hypoparathyroidism
AU2016275735B2 (en) 2015-06-12 2020-02-06 Novo Nordisk A/S Selective PYY compounds and uses thereof
WO2017060500A1 (en) 2015-10-07 2017-04-13 Cyprumed Gmbh Pharmaceutical formulations for the oral delivery of peptide drugs
AR112015A1 (es) 2017-06-09 2019-09-11 Novo Nordisk As Composiciones sólidas para administración oral
CN111683676B (zh) 2018-02-02 2024-06-18 诺和诺德股份有限公司 包含glp-1激动剂、n-(8-(2-羟基苯甲酰基)氨基)辛酸的盐和润滑剂的固体组合物

Also Published As

Publication number Publication date
KR20140138873A (ko) 2014-12-04
PL2827885T3 (pl) 2019-01-31
CN107812181A (zh) 2018-03-20
EP3488857A1 (en) 2019-05-29
JP2015512374A (ja) 2015-04-27
EP2827885B1 (en) 2018-08-15
AU2013234496B2 (en) 2017-07-27
US20210162012A1 (en) 2021-06-03
US11759503B2 (en) 2023-09-19
EP3488857B1 (en) 2023-06-07
RS64460B1 (sr) 2023-09-29
US11759501B2 (en) 2023-09-19
RU2014141700A (ru) 2016-05-20
AU2017251814B2 (en) 2019-06-13
US11759502B2 (en) 2023-09-19
HUE062740T2 (hu) 2023-12-28
JP6001158B2 (ja) 2016-10-05
PL3488857T3 (pl) 2023-12-11
MX2014010685A (es) 2014-10-13
US20150072926A1 (en) 2015-03-12
RU2641198C2 (ru) 2018-01-16
MX353067B (es) 2017-12-19
US20220362346A1 (en) 2022-11-17
KR102072202B1 (ko) 2020-01-31
LT2827885T (lt) 2018-10-10
US10933120B2 (en) 2021-03-02
CN107812181B (zh) 2022-06-17
EP3488857B9 (en) 2023-10-04
RS57727B1 (sr) 2018-12-31
DK2827885T3 (en) 2018-10-08
HRP20231060T1 (hr) 2023-12-22
HRP20181447T1 (hr) 2018-11-02
BR112014023374A8 (pt) 2018-01-16
EP4324475A1 (en) 2024-02-21
US20240016897A1 (en) 2024-01-18
CN104203266B (zh) 2017-12-26
CA2868188A1 (en) 2013-09-26
AU2013234496A1 (en) 2014-09-11
US20220331404A1 (en) 2022-10-20
ZA201406250B (en) 2022-05-25
BR112014023374B1 (pt) 2021-09-21
EP2827885A1 (en) 2015-01-28
SI2827885T1 (sl) 2018-10-30
BR112014023374A2 (pt) 2017-07-11
AU2017251814A1 (en) 2017-11-16
WO2013139694A1 (en) 2013-09-26
EP3488857C0 (en) 2023-06-07
ES2690553T3 (es) 2018-11-21
ES2952874T3 (es) 2023-11-06
CN104203266A (zh) 2014-12-10
MY171146A (en) 2019-09-27
HUE039406T2 (hu) 2018-12-28

Similar Documents

Publication Publication Date Title
RU2641198C3 (ru) Композиции glp-1 пептидов и их получение
HRP20231613T1 (hr) Pripravci koji sadrže sredstvo za unošenje i njihova priprava
JP2015515459A5 (ru)
RU2015147876A (ru) Пероральная дозированная форма соединений глюкагоноподобного пептида-1
RU2470016C2 (ru) Производное бипиразола
HRP20231205T1 (hr) Čvrsti pripravci koji sadrže agonist glp-1, sol n-(8-(2- hidroksibenzoil)amino)kaprilne kiseline i mazivo
JP2015512374A5 (ru)
HRP20180425T1 (hr) Čvrste kompozicije koje sadrže agonist glp-1 i sol n-(8-(2-hidroksibenzoil)amino)kaprilne kiseline
JP2016519128A5 (ru)
NO20091501L (no) Farmasoytiske sammensetninger
JP2013199505A5 (ru)
RU2016122609A (ru) Составы соединений азаиндола
JP2015522630A5 (ru)
EA201490014A1 (ru) Модифицированное высвобождение 4-метил-3-[[4-(3-пиридинил)-2-пиримидинил]амино]-n-[5-(4-метил-1h-имидазол-1-ил)-3-(трифторметил)фенил]бензамида, солюбилизированного с использованием органических кислот
HRP20201736T1 (hr) Postupak liječenja diskinezije
RU2017107760A (ru) Соединение
EA200901146A1 (ru) Твердые лекарственные формы, содержащие алискирен и его фармацевтически приемлемые соли
RU2007132971A (ru) Способы и материалы с транс-кломифеном для лечения мужского бесплодия
RU2012131959A (ru) Способ лечения остеоартрита
JP2014527506A5 (ru)
RU2006115784A (ru) Применение l-бутилфталида для изготовления лекарственного средства для профилактики и лечения церебрального инфаркта
RU2016103764A (ru) Стабилизированные фармацевтические лекарственные формы, содержащие атрасентан
JP2011516544A5 (ru)
RU2015113031A (ru) Использование 3-n-бутил изоиндолин кетонов при приготовлении лекарственных средств для профилактики и лечения церебрального инфаркта
JP2012046484A5 (ru)

Legal Events

Date Code Title Description
ND4A Extension of patent duration

Effective date: 20211210